A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination * Have a body mass index of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive Exclusion Criteria: * Have known allergies to Lasmiditan, Sumatriptan, related compounds, or any components of the formulations of Lasmiditan and Sumatriptan * Have a history of, or electrocardiogram (ECG) findings of, clinically significant bradycardia, heart block, tachy or brady arrhythmias * Have a history, signs, or symptoms of arrhythmia or Wolff Parkinson White syndrome that could affect the participant's safety * Have an estimated glomerular filtration rate (eGFR) of less than (\<) 60 milliliter per minute (mL/min) per 1.73 m² * Have a resting systolic blood pressure (SBP) greater than (\>) 135 millimeters of mercury (mmHg) and diastolic blood pressure (DBP) \>85 mmHg at screening * Have a supine pulse rate (PR) of \<50 or \>90 beats per minute (bpm) at screening * Have a history, signs, or symptoms of vasospastic coronary artery disease * Have known or ongoing neuropsychiatric disorders (for example, manic depressive illness, schizophrenia, depression) considered as clinically significant by the investigator * Use of monoamine oxidase-A inhibitors and other drugs associated with serotonin within the 3 months prior to the first dosing occasion